<DOC>
	<DOC>NCT01342016</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and safety of tacrolimus capsules with leflunomide tablets in the treatment of lupus nephritis.</brief_summary>
	<brief_title>A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>body weight 40100kg diagnosed as systemic lupus erythematosus, (according to American College of Rheumatology Diagnostic Criteria,1997) diagnosed as type III/ IV of lupus nephritis by renal biopsy within 6 months 24hr proteinuria ≥2g and/or active urinary sediments receiving immunosuppressant receiving routine treatment of tacrolimus and leflunomide within 1 month receiving nonsteroidal antiinflammatory drugs (NSAIDs) within 1 months before the study history of allergy to tacrolimus and leflunomide anticipated maintenance dialysis persisted over 8 weeks; or already being dialyzed over 2 weeks before recruitment planning to receive kidney transplantation or in the near future or having a history of undergoing kidney transplantation serum creatinine (Scr) ≥3mg/dl or estimated glomerular filtration rate (eGFR) &lt; 30ml/min diabetes mellitus patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>prograf</keyword>
	<keyword>nephritis</keyword>
	<keyword>leflunomide</keyword>
	<keyword>immunosuppressant</keyword>
</DOC>